Opinion

Video

Considerations for Maintenance Therapy in the Community Oncology Setting

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Ke Ning, MD

Key opinion leaders address the importance of coordination between academic hospital providers and community oncologists when transitioning from initiation of bispecific antibodies at a tertiary hospital to maintenance therapy in the community oncology setting.

Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
Outpatient Transplant and CAR T-Cell Therapy: A Paradigm Shift in Care Delivery
November 19th 2024

Outpatient Transplant and CAR T-Cell Therapy: A Paradigm Shift in Care Delivery

Alana Hippensteele, Managing Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

Multiple myeloma cells | Image Credit: © Сергей Косилко - stock.adobe.com
November 11th 2024

Johnson & Johnson Seeks FDA Approval of Daratumumab for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Image Credit: © CHA - stock.adobe.com
November 6th 2024

Bone Marrow Adipocytes May Offer Early Detection of MGUS Progression to Multiple Myeloma

Alexandra Gerlach, Associate Editor
Image Credit: © Сергей Косилко - stock.adobe.com
November 1st 2024

Carfilzomib, Lenalidomide, and Dexamethasone: A Curative Approach for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Biliary tract cancer -- Image credit: Thipphaphone | stock.adobe.com
October 30th 2024

Emerging Therapies and Precision Medicine Offer Promising Results in Hepatocellular Carcinoma and Biliary Tract Cancer

Gabriela Aponte-Melendez, PharmD Nicole Bentivegna, PharmD, BCOP